Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301

EISAKU MIYAUCHI, a AKIRA INOUE, b KAZUHIRO USUI, c SHUNICHI SUGAWARA, d MAKOTO MAEMONDO, e HEISUKE SAITO, f YUKA FUJITA, g TERUFUMI KATO, h TOSHIRO SUZUKI, i TOSHIYUKI HARADA, j HIROSHI WATANABE, k TAKU NAKAGAWA, l MASAKAZU ICHINOSE a

aDepartment of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan; bDepartment of Palliative Medicine, Tohoku University School of Medicine, Sendai, Japan; cDivision of Respiriology, NTT Medical Center Tokyo, Tokyo, Japan; dDepartment of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan; eDepartment of Respiratory Medicine, Miyagi Cancer Center, Natori, Japan; fDepartment of Respiratory Medicine, Iwate Medical University Hospital, Morioka, Japan; gDepartment of Respiratory Medicine, Asahikawa Medical Center, Asahikawa, Japan; hDepartment of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; iDepartment of Respiratory Medicine, Isawa Hospital, Fuefuki, Japan; jCenter for Respiratory Diseases, JCHO Hokkaido Hospital, Sapporo, Japan; kDepartment of Respiratory Medicine, Saka General Hospital, Shiogama, Japan; lThoracic Surgery, Omagari-Kosei Medical Center, Daisen, Japan

**TRIAL INFORMATION**

- **UMIN-CTR Identifier:** UMIN000010324
- **Sponsor:** North Japan Lung Cancer Study Group
- **Principal Investigator:** Eisaku Miyauchi
- **IRB Approved:** Yes

**LESSONS LEARNED**

- Weekly nanoparticle albumin-bound-paclitaxel (75 mg/m²) in combination with carboplatin (area under the curve 6 mg/mL/min) in elderly patients with previously untreated, advanced non-small cell lung cancer showed favorable efficacy, was well tolerated, and showed less neuropathic toxicity.
- This modified regimen offers potential for the treatment of elderly patients.

**ABSTRACT**

**Background.** The CA031 trial suggested weekly nanoparticle albumin-bound-paclitaxel (nab-PTX) was superior in efficacy to paclitaxel (PTX) once every 3 weeks when combined with carboplatin (CBDCA) for advanced non-small cell lung cancer (NSCLC) patients; a subgroup analysis of elderly patients looked promising. In a multicenter phase II trial, we prospectively evaluated the efficacy and tolerability of modified CBDCA plus weekly nab-PTX for elderly patients with untreated advanced NSCLC.

**Methods.** Eligible patients received CBDCA (area under the curve [AUC] 6 mg/mL/min) on day 1 and nab-PTX (75 mg/m²) on days 1, 8, and 15 every 4 weeks. The primary endpoint was an overall response rate (ORR), and secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity.

**Results.** Of 32 patients (median age of 78 years), 84% were male, 56% had stage IV NSCLC, and 56% had squamous cell carcinoma. ORR and disease control rates were 50% (95% confidence interval [CI]: 33–67) and 94% (95% CI: 85–100), respectively. Median PFS and OS were 6.4 months (95% CI: 4.8–8.0) and 17.5 months (95% CI: 11.9–23.1), respectively. Grade ≥3 toxicities were neutropenia (47%), leukopenia (38%), anemia (34%), thrombocytopenia (25%), and anorexia (9%). Febrile neutropenia and treatment-related deaths were not observed.

**Conclusion.** Modified CBDCA plus weekly nab-PTX demonstrated significant efficacy and acceptable toxicities in elderly patients with advanced NSCLC. *The Oncologist* 2017;22:640–e59

**DISCUSSION**

This prospective study was designed to investigate the efficacy and safety of modified CBDCA combined with weekly nab-PTX as first-line chemotherapy in elderly patients with advanced NSCLC. Socinski et al. analyzed the efficacy and toxicity of CBDCA combined with nab-PTX in elderly patients (≥70 years old) in the CA031 study and revealed the ORR was 32% and the median OS was 19.9 months [1]. An ORR of 50% and an OS of 17.5 months in the present study are consistent with the CA031 study, although our study was intended for patients ≥75 years of age, and the median weekly dose intensity was less than that used in the CA031 study (45 mg/m² vs. 73.4 mg/m²).

Correspondence: Eisaku Miyauchi, M.D., Ph.D., Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, 1-1, Seiryo-machi, Aoba-ku, Sendai, Miyagi, Sendai, Japan 980-8574. Telephone: 81-22-717-8539; e-mail: miyauchi@rm.med.tohoku.ac.jp Received December 25, 2016; accepted for publication February 17, 2017; published Online First on May 19, 2017. ©AlphaMed Press; the data published online to support this summary is the property of the authors. https://doi.org/10.1634/theoncologist.2017-0059
Quoix et al. recently reported on IFCT-0501, a phase III study comparing CBDCA (AUC 6 mg/mL/min on day 1 every 4 weeks) plus PTX (90 mg/m² on days 1, 8, and 15 every 4 weeks) with monotherapy with vinorelbine or gemcitabine in elderly patients with advanced NSCLC [2]. The median OS was significantly longer in the doublet group than in the monotherapy group. Similar to the IFCT-0501 trial, we previously demonstrated the high efficacy of CBDCA (AUC 6 mg/mL/min on day 1 every 4 weeks) plus weekly PTX (70 mg/m² on days 1, 8, and 15 every 4 weeks) compared with single-agent docetaxel for elderly patients with NSCLC [3]. We have also reported on a randomized phase II trial of weekly PTX combined with CBDCA (same as above) versus standard PTX combined with CBDCA (210 mg/m² and AUC 6 mg/mL/min on day 1 every 3 weeks) for elderly patients with advanced NSCLC [4]. Regarding the efficacy of CBDCA plus nab-PTX, the ORR and PFS (50%, 6.4 months) attained are consistent with the results achieved with a CBDCA plus weekly PTX regimen in our previous two studies (55%, 6.0 months and 54%, 6.6 months, respectively) [3, 4].

Regarding the toxicity of modified carboplatin plus weekly nab-paclitaxel, its adverse event (AE) profile was tolerable. Nonhematological toxicities were acceptable, with the most frequent AEs being anorexia, alopecia, and nausea. Also, the relatively lower incidences of sensory neuropathy resulting in the discontinuation of treatment were similar to those seen in patients treated with CBDCA plus nab-PTX in the CA031 study [1, 5]. Our data support the feasibility of a modified regimen of CBDCA plus a lower dose of nab-PTX for elderly patients. In addition to fewer AEs, because nab-PTX does not contain solvents, unlike PTX, it is not usually necessary to take premedications, such as H1 and H2 blockers and steroids, to prevent allergic reactions prior to the administration of nab-PTX [6–9]. Therefore, nab-PTX may be a more acceptable drug option than PTX for elderly lung cancer patients.

**Figure 1.** Tumor shrinkage by histological type. Blue bars: squamous cell carcinoma, n = 18. Orange bars: adenocarcinoma, n = 14.

---

### Trial Information

| Disease                | Lung cancer – NSCLC |
|------------------------|---------------------|
| Stage of disease/treatment | Metastatic/Advanced |
| Prior therapy          | None                |
| Type of study – 1      | Phase II            |
| Type of study – 2      | Single arm          |
| Primary endpoint       | Overall response rate |
| Secondary endpoint     | Progression free survival |
| Secondary endpoint     | Overall survival    |
| Secondary endpoint     | Toxicity            |

### Additional details of endpoints or study design

Patients. Eligible patients were aged 75 years or older, with histologically or cytologically confirmed NSCLC that was classified as either clinical stage IIIb, IV, or a postoperative recurrence. Other eligibility criteria for patients included being previously untreated and having had at least one unidimensionally measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST), an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and an estimated life expectancy >12 weeks. Laboratory criteria included a hemoglobin concentration ≥9 g/dL, a neutrophil count ≥1,500/mm³, a platelet count ≥100,000/mm³, aspartate transaminase and alanine transaminase <100 IU/L, serum creatinine 1.5 mg/dL, and PaO₂ >60 mmHg. Exclusion criteria included peripheral neuropathy with Common Terminology Criteria for Adverse Events (CTCAE) grade ≥2, prior treatment with PTX as adjuvant chemotherapy, progressive brain metastases, or uncontrolled third-space fluid retention prior to study entry. Patients were also excluded if they had an active infection, interstitial pneumonia, active lung fibrosis, an active synchronous cancer, or a history of allergy or hypersensitivity to drugs. An institutional review board at each hospital approved this study, and written, informed consent was obtained from all enrolled patients.

Study Design and Treatment Plan. This multicenter, single arm, phase II study evaluated the efficacy and safety of a 75 mg/m² infusion of nab-PTX on days 1, 8, and 15, followed by a CBDCA AUC of 6 mg/mL/min (per Calvert formula) on day 1 every 4 weeks, as first-line chemotherapy in patients with advanced NSCLC. Treatment of at least four cycles was encouraged unless disease progression or unacceptable toxicities were observed. Second-line chemotherapy or other treatments after this study were not prohibited by the protocol. Patients who had an epidermal growth factor receptor (EGFR) mutation received EGFR tyrosine kinase inhibitor after progression to this study treatment according to the protocol.

Assessment of Efficacy and Safety Endpoints. The primary endpoint of this study was the ORR and the rate of complete response (CR) and/or partial response (PR) as confirmed by a blinded, centralized, independent review according to RECIST. Computed
tomography scans were performed every 4 weeks from screening until disease progression. Secondary endpoints were PFS, OS, and toxicity profile. The follow-up period was 18 months after the last patient enrollment.

Statistical Methods. The minimum number of patients enrolled in the present study was 32 assuming an expected response rate (RR) of 40% and a threshold RR of 20% with an $\alpha$ error of 0.05 (one-sided) and a $\beta$ error of 0.2. Assuming that about 10% of patients would eventually not qualify, at least 35 patients needed to be recruited. The primary analysis of the ORR was planned in qualified patients, defined as receiving at least one course of nab-PTX and CBDCA. PFS and OS were analyzed using Kaplan-Meier methods. Safety analyses summarized AEs by maximum CTCAE grade, and whether or not they were serious, during the entire treatment period.

**Investigator’s Analysis**

| Active and should be pursued further |

### Drug Information

| Drug 1 | | | |
| --- | --- | --- | --- |
| **Generic/Working name** | Nanoparticle albumin-bound-paclitaxel | | |
| **Trade name** | Abraxane | | |
| **Company name** | Taiho Pharma | | |
| **Drug type** | Chemotherapy | | |
| **Drug class** | Microtubule-targeting agent | | |
| **Dose** | 75 milligrams (mg) per square meter (m²) | | |
| **Route** | IV | | |
| **Schedule of administration** | Day 1, 8, and 15 every 4 weeks | | |

| Drug 2 | | | |
| --- | --- | --- | --- |
| **Generic/Working name** | Carboplatin | | |
| **Trade name** | Paraplatin | | |
| **Company name** | Bristol-Myers Squibb | | |
| **Drug type** | Chemotherapy | | |
| **Drug class** | Platinum compound | | |
| **Dose** | AUC 6 mg/mL/min | | |
| **Route** | IV | | |
| **Schedule of administration** | Day 1 every 4 weeks | | |

### Patient Characteristics for Phase II Control Arm

| Number of patients, male | 27 |
| Number of patients, female | 5 |
| Stage | Illb: 7 IV: 18 Postoperative recurrence: 7 |
| Age | Median (range): 78(75–86) |
| Number of prior systemic therapies | Median (range): 0 |
| Performance status: ECOG | 0 — 16 1 — 16 2 — 3 — unknown — |
| Other: EGFR mutation status | Mutant: 2 Wild: 16 Unknown: 14 |
| Cancer types or histologic subtypes | Adenocarcinoma: 14 Squamous cell carcinoma: 18 |
**ADVERSE EVENTS**

| Adverse Event                | All grade | Grade 3 | Grade 4 | Grade 3/4 |
|------------------------------|-----------|---------|---------|-----------|
| **Hematological**            |           |         |         |           |
| Leukopenia                   | 27 (84.4) | 11 (34.4) | 1 (3.1) | 12 (37.5) |
| Neutropenia                  | 25 (78.1) | 9 (28.1)  | 6 (18.8) | 15 (46.9) |
| Anemia                       | 31 (96.9) | 11 (34.4) | 0       | 11 (34.4) |
| Thrombocytopenia             | 26 (81.3) | 6 (18.8)  | 2 (6.3)  | 8 (25.0)  |
| Febrile neutropenia          | 0         |          |         |           |
| **Nonhematological**         |           |         |         |           |
| Infection                    | 4 (12.5)  | 1 (3.1)  | 0       | 1 (3.1)   |
| Fever                        | 6 (18.8)  | 0        | 0       | 0         |
| Anorexia                     | 21 (65.6) | 3 (9.4)  | 0       | 3 (9.4)   |
| Nausea                       | 15 (46.9) | 2 (6.3)  | 0       | 2 (6.3)   |
| Vomiting                     | 1 (3.1)   | 0        | 0       | 0         |
| Fatigue                      | 11 (34.4) | 2 (6.3)  | 0       | 2 (6.3)   |
| Diarrhea                     | 1 (3.1)   | 0        | 0       | 0         |
| Pneumonitis                  | 2 (6.3)   | 1 (3.1)  | 0       | 1 (3.1)   |
| Alopecia                     | 20 (62.5) | 0        | 0       | 0         |
| Peripheral sensory neuropathy| 6 (18.8)  | 1 (3.1)  | 0       | 1 (3.1)   |
| Myalgia                      | 3 (9.4)   | 0        | 0       | 0         |
| Arthralgia                   | 4 (12.5)  | 0        | 0       | 0         |
| Gastrointestinal hemorrhage  | 2 (6.3)   | 2 (6.3)  | 0       | 2 (6.3)   |
| Lower gastrointestinal perforation | 1 (3.1) | 0       | 1 (3.1) | 1 (3.1)   |
| Mucositis oral               | 1 (3.1)   | 0        | 0       | 0         |
| Weight loss                  | 1 (3.1)   | 0        | 0       | 0         |

**PRIMARY ASSESSMENT METHOD FOR PHASE II CONTROL ARM**

**Control Arm: Total Patient Population**
- Number of patients screened: 35
- Number of patients enrolled: 35
- Number of patients evaluable for toxicity: 32
- Number of patients evaluated for efficacy: 32

**Response assessment**
- CR: 5 (13.1%) (Median) duration assessments PFS: 6.4 months, CI: 4.8–8.0
- PR: 15 (46.9%)
- SD: 14 (43.8%)
- PD: 2 (6.3%)
- OTHER: 0 (0%)

**(Median) duration assessments OS: 17.5 months, CI: 11.9–23.1**

**ASSESSMENT, ANALYSIS, AND DISCUSSION**

Completion
- Study completed

Pharmacokinetics/Pharmacodynamics
- Not Collected

Investigator’s assessment
- Active and should be pursued further
Lung cancer is the most common cause of death from cancer in the elderly population. With many countries facing an aging population, the incidence of lung cancer in this age group is expected to increase. Consequently, it has become increasingly important to establish more effective treatments for elderly patients with advanced non-small cell lung cancer (NSCLC). A recent IFCT-0501 trial demonstrated that carboplatin (CBDCA) combined with weekly paclitaxel (PTX) would be advantageous, compared with vinorelbine or gemcitabine monotherapy, for elderly patients with previously untreated, advanced NSCLC [2]. Subsequently, the CA031 trial suggested that weekly nanoparticle albumin-bound-PTX (nab-PTX) was superior in efficacy and safety compared with PTX once every 3 weeks when combined with CBDCA [1, 5]. In addition, a subgroup analysis of elderly patients in the CA031 trial yielded very promising data (a 34% overall response rate [ORR] and 8 months of progression-free survival [PFS]), whereas in a Japanese subgroup analysis, many cases required the omission of treatments as well as a reduction in doses [10]. We therefore conducted this multicenter, nonrandomized, open-label, phase II trial to prospectively evaluate the efficacy and tolerability of a modified CBDCA plus weekly nab-PTX regimen for elderly patients with previously untreated, advanced NSCLC. The ORR met our primary endpoint and supported the favorable efficacy of this combination among an elderly population, as found in the CA031 trial [5].

We also evaluated the ORR by histologic type. Satouchi et al. reported that a Japanese subset analysis of the CA031 study showed more effectiveness in the squamous cell carcinoma subset than in nonsquamous cell carcinoma [10]. Although a similar tendency was shown in this study, because of the small sample size, a significant difference was not observed between adenocarcinoma and squamous cell carcinoma in terms of ORR and PFS. Recently, several studies have confirmed the effectiveness of nab-PTX with CBDCA in patients with squamous cell carcinoma [11]. Further study is needed to determine the difference in effects for both histological types.

The present study had several limitations. First, this study used a small sample size and, for this reason, future phase III studies will be required to evaluate the effectiveness of this modified regimen, although promising results were obvious in this study. Concerning this limitation, the CAPITAL study, a randomized phase III trial of CBDCA plus nab-PTX versus docetaxel for squamous NSCLC in the elderly, is ongoing in Japan. Second, the present study lacked a quality-of-life (QoL) assessment. Most elderly patients with advanced NSCLC do not have curative treatment options, and, therefore, the goal of therapy for such patients is a prolongation of survival without negatively impacting QoL. From this perspective, we plan to evaluate QoL in a future, randomized phase III trial of modified CBDCA plus nab-PTX for elderly patients with advanced NSCLC.

In conclusion, weekly nab-PTX (75 mg/m²) in combination with CBDCA (AUC 6 mg/mL/min) in elderly patients with previously untreated, advanced NSCLC showed favorable efficacy, was well tolerated, and showed less neuropathic toxicity. Therefore, nab-PTX offers several distinct advantages over conventional PTX when combined with CBDCA. Based on our results, even if the high cost of nab-PTX is considered, we believe that a modified CBDCA plus weekly nab-PTX regimen should be used for elderly patients regarding efficacy and tolerability. Future phase III studies will be needed to further evaluate the role of weekly nab-PTX in combination with CBDCA for such patients.

Acknowledgements

The authors thank all patients, families, and investigators participating in the NJLCG1301 study.

Disclosures

Akira Inoue: Taiho (H); Shunichi Sugawara: AstraZeneca, Chugai, Nippon Boehringer Ingelheim, Pfizer, Taiho, Eli Lilly and Company, Novartis, Kyowa Hakko Kirin, Bristol-Myers Squibb, Ono (H); Makoto Maemondo: Bristol-Myers Squibb (H). The other authors indicated no financial relationships.

(CA) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/inventor/patient holder; (SAB) Scientific advisory board

References

1. Socinski MA, Langer CJ, Okamoto I et al. Safety and efficacy of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer. Ann Oncol 2013;24:314–321.
2. Quoix E, Zalcman G, Oster JP et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0001 randomised, phase 3 trial. Lancet 2011;378:1079–1088.
3. Maemondo M, Inoue A, Sugawara S et al. Randomized phase II trial comparing carboplatin plus weekly paclitaxel and docetaxel alone in elderly patients with advanced non-small-cell lung cancer: North Japan Lung Cancer Group Trial 0801. The Oncologist 2014;19:352–353.
4. Sakakibara T, Inoue A, Sugawara S et al. Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer. Ann Oncol 2010;21:795–799.
5. Socinski MA, Bondarenko I, Karaseva NA et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Final results of a phase III trial. J Clin Oncol 2012;30:2055–2062.
6. Ten Tije AJ, Verweij J, Loos WJ et al. Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy. Clin Pharmacokinet 2003;42:665–685.
7. Desai N, Trieu V, Yao Z et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006;12:1317–1324.
8. Gupta N, Hatoum H, Dy GK. First line treatment of advanced non-small-cell lung cancer-specific focus on albumin bound paclitaxel. Int J Nanomedicine 2014;9:209–221.
9. Hirsh V. Nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer. Expert Rev Anticancer Ther 2014;14:129–141.
10. Satouchi M, Okamoto I, Sakai H et al. Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small-cell lung cancer. Lung Cancer 2013;81:97–101.
11. Simon GR. Nab-Paclitaxel for the treatment of advanced squamous non-small-cell lung cancer: A comprehensive update. Clin Lung Cancer 2014;15:391–397.

Click here to access other published clinical trials.